CN108368155A - 人源性免疫抑制蛋白和肽作为药物的应用 - Google Patents

Info

Publication number

CN108368155A

CN108368155A CN201680070131.4A CN201680070131A CN108368155A CN 108368155 A CN108368155 A CN 108368155A CN 201680070131 A CN201680070131 A CN 201680070131A CN 108368155 A CN108368155 A CN 108368155A

Authority

CN

China

Prior art keywords

amino acid

polypeptide

seq

protein

disease

Prior art date

2015-10-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 549
• 108090000623 proteins and genes Proteins 0.000 title claims description 262
• 102000004169 proteins and genes Human genes 0.000 title claims description 212
• 239000003814 drug Substances 0.000 title claims description 67
• 229940079593 drug Drugs 0.000 title claims description 51
• 230000006028 immune-suppresssive effect Effects 0.000 title description 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 423
• 206010061218 Inflammation Diseases 0.000 claims abstract description 62
• 230000004054 inflammatory process Effects 0.000 claims abstract description 62
• 229920001184 polypeptide Polymers 0.000 claims description 348
• 150000001413 amino acids Chemical class 0.000 claims description 217
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 151
• 201000010099 disease Diseases 0.000 claims description 145
• 150000007523 nucleic acids Chemical class 0.000 claims description 131
• 239000013604 expression vector Substances 0.000 claims description 130
• 102000039446 nucleic acids Human genes 0.000 claims description 125
• 108020004707 nucleic acids Proteins 0.000 claims description 125
• 239000008194 pharmaceutical composition Substances 0.000 claims description 122
• 108090001005 Interleukin-6 Proteins 0.000 claims description 71
• 102000004889 Interleukin-6 Human genes 0.000 claims description 71
• 230000014509 gene expression Effects 0.000 claims description 71
• 208000023275 Autoimmune disease Diseases 0.000 claims description 58
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 49
• 206010003246 arthritis Diseases 0.000 claims description 48
• 238000011282 treatment Methods 0.000 claims description 46
• 239000000203 mixture Substances 0.000 claims description 41
• 230000000694 effects Effects 0.000 claims description 38
• 238000000034 method Methods 0.000 claims description 37
• -1 carrier Substances 0.000 claims description 31
• 230000003405 preventing effect Effects 0.000 claims description 31
• 230000006798 recombination Effects 0.000 claims description 31
• 238000005215 recombination Methods 0.000 claims description 30
• 241000700605 Viruses Species 0.000 claims description 29
• 230000002757 inflammatory effect Effects 0.000 claims description 26
• 238000006471 dimerization reaction Methods 0.000 claims description 25
• 206010040047 Sepsis Diseases 0.000 claims description 19
• 239000003085 diluting agent Substances 0.000 claims description 19
• 230000035772 mutation Effects 0.000 claims description 19
• 230000009885 systemic effect Effects 0.000 claims description 17
• 239000000178 monomer Substances 0.000 claims description 16
• 230000001684 chronic effect Effects 0.000 claims description 15
• 239000007924 injection Substances 0.000 claims description 14
• 238000002347 injection Methods 0.000 claims description 14
• 206010020751 Hypersensitivity Diseases 0.000 claims description 13
• 230000001154 acute effect Effects 0.000 claims description 13
• 239000000853 adhesive Substances 0.000 claims description 13
• 230000001070 adhesive effect Effects 0.000 claims description 13
• 208000026935 allergic disease Diseases 0.000 claims description 13
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
• 239000002904 solvent Substances 0.000 claims description 13
• 208000006673 asthma Diseases 0.000 claims description 12
• 230000004957 immunoregulator effect Effects 0.000 claims description 12
• 230000002265 prevention Effects 0.000 claims description 12
• 238000002560 therapeutic procedure Methods 0.000 claims description 12
• 239000002671 adjuvant Substances 0.000 claims description 9
• 230000007815 allergy Effects 0.000 claims description 9
• 230000004927 fusion Effects 0.000 claims description 9
• 238000001990 intravenous administration Methods 0.000 claims description 9
• 201000006417 multiple sclerosis Diseases 0.000 claims description 9
• 238000007920 subcutaneous administration Methods 0.000 claims description 9
• 238000010171 animal model Methods 0.000 claims description 8
• 230000004968 inflammatory condition Effects 0.000 claims description 8
• 238000000926 separation method Methods 0.000 claims description 8
• 229960005486 vaccine Drugs 0.000 claims description 8
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 238000007918 intramuscular administration Methods 0.000 claims description 7
• 230000006872 improvement Effects 0.000 claims description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
• 210000000436 anus Anatomy 0.000 claims description 4
• 238000002405 diagnostic procedure Methods 0.000 claims description 4
• 241000588724 Escherichia coli Species 0.000 claims description 3
• 210000003928 nasal cavity Anatomy 0.000 claims description 3
• 231100000614 poison Toxicity 0.000 claims description 3
• 210000001215 vagina Anatomy 0.000 claims description 3
• 239000002574 poison Substances 0.000 claims description 2
• 230000029305 taxis Effects 0.000 claims 1
• 239000003018 immunosuppressive agent Substances 0.000 abstract description 27
• 229960003444 immunosuppressant agent Drugs 0.000 abstract description 26
• 230000001861 immunosuppressant effect Effects 0.000 abstract description 26
• 241000713887 Human endogenous retrovirus Species 0.000 abstract description 19
• 230000033228 biological regulation Effects 0.000 abstract description 7
• 230000001900 immune effect Effects 0.000 abstract description 7
• 210000004027 cell Anatomy 0.000 description 194
• 235000018102 proteins Nutrition 0.000 description 185
• 235000001014 amino acid Nutrition 0.000 description 164
• 229940100601 interleukin-6 Drugs 0.000 description 65
• 239000000463 material Substances 0.000 description 61
• 238000002513 implantation Methods 0.000 description 54
• 241000699666 Mus <mouse, genus> Species 0.000 description 49
• 241001430294 unidentified retrovirus Species 0.000 description 47
• 208000011580 syndromic disease Diseases 0.000 description 40
• 230000001363 autoimmune Effects 0.000 description 34
• 230000001506 immunosuppresive effect Effects 0.000 description 29
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 28
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 28
• 238000011160 research Methods 0.000 description 27
• 239000012620 biological material Substances 0.000 description 26
• 230000006870 function Effects 0.000 description 25
• 108090000695 Cytokines Proteins 0.000 description 24
• 150000001875 compounds Chemical class 0.000 description 24
• 102000004127 Cytokines Human genes 0.000 description 23
• 241000578472 Human endogenous retrovirus H Species 0.000 description 23
• 230000028993 immune response Effects 0.000 description 21
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 21
• 206010034277 Pemphigoid Diseases 0.000 description 19
• 230000015572 biosynthetic process Effects 0.000 description 19
• 230000000903 blocking effect Effects 0.000 description 18
• 239000002158 endotoxin Substances 0.000 description 18
• 229920006008 lipopolysaccharide Polymers 0.000 description 18
• 239000000126 substance Substances 0.000 description 18
• 230000006378 damage Effects 0.000 description 17
• 239000000523 sample Substances 0.000 description 17
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 16
• 102100034349 Integrase Human genes 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 16
• 210000001744 T-lymphocyte Anatomy 0.000 description 16
• 206010047115 Vasculitis Diseases 0.000 description 16
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
• 206010018910 Haemolysis Diseases 0.000 description 15
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 15
• 102000003814 Interleukin-10 Human genes 0.000 description 15
• 108090000174 Interleukin-10 Proteins 0.000 description 15
• 230000008859 change Effects 0.000 description 15
• 108020004999 messenger RNA Proteins 0.000 description 15
• 229920000642 polymer Polymers 0.000 description 15
• 238000012545 processing Methods 0.000 description 15
• 238000003786 synthesis reaction Methods 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• 208000006454 hepatitis Diseases 0.000 description 14
• 238000010172 mouse model Methods 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 101710091045 Envelope protein Proteins 0.000 description 13
• 101710188315 Protein X Proteins 0.000 description 13
• 230000002917 arthritic effect Effects 0.000 description 13
• 230000008588 hemolysis Effects 0.000 description 13
• 231100000283 hepatitis Toxicity 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 239000002674 ointment Substances 0.000 description 13
• 230000000770 proinflammatory effect Effects 0.000 description 13
• 208000024891 symptom Diseases 0.000 description 13
• 206010028980 Neoplasm Diseases 0.000 description 12
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
• 201000011510 cancer Diseases 0.000 description 12
• 238000011161 development Methods 0.000 description 12
• 230000018109 developmental process Effects 0.000 description 12
• 208000015181 infectious disease Diseases 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 239000002245 particle Substances 0.000 description 12
• 208000032514 Leukocytoclastic vasculitis Diseases 0.000 description 11
• 125000000539 amino acid group Chemical group 0.000 description 11
• 239000000539 dimer Substances 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 description 10
• 208000007465 Giant cell arteritis Diseases 0.000 description 10
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
• 208000012309 Linear IgA disease Diseases 0.000 description 10
• 208000012192 Mucous membrane pemphigoid Diseases 0.000 description 10
• 208000006045 Spondylarthropathies Diseases 0.000 description 10
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 10
• 230000005784 autoimmunity Effects 0.000 description 10
• 201000010002 cicatricial pemphigoid Diseases 0.000 description 10
• 239000001963 growth medium Substances 0.000 description 10
• 229960000485 methotrexate Drugs 0.000 description 10
• 239000002105 nanoparticle Substances 0.000 description 10
• 239000002773 nucleotide Substances 0.000 description 10
• 125000003729 nucleotide group Chemical group 0.000 description 10
• 230000000750 progressive effect Effects 0.000 description 10
• 201000005671 spondyloarthropathy Diseases 0.000 description 10
• 210000003371 toe Anatomy 0.000 description 10
• 206010015150 Erythema Diseases 0.000 description 9
• 102000000589 Interleukin-1 Human genes 0.000 description 9
• 108010002352 Interleukin-1 Proteins 0.000 description 9
• 108090001007 Interleukin-8 Proteins 0.000 description 9
• 102000004890 Interleukin-8 Human genes 0.000 description 9
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 9
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• 206010014599 encephalitis Diseases 0.000 description 9
• 231100000321 erythema Toxicity 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 206010025135 lupus erythematosus Diseases 0.000 description 9
• 239000000825 pharmaceutical preparation Substances 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 230000002103 transcriptional effect Effects 0.000 description 9
• 238000001890 transfection Methods 0.000 description 9
• 208000008190 Agammaglobulinemia Diseases 0.000 description 8
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 8
• 208000015943 Coeliac disease Diseases 0.000 description 8
• 208000011231 Crohn disease Diseases 0.000 description 8
• 238000002965 ELISA Methods 0.000 description 8
• 206010018364 Glomerulonephritis Diseases 0.000 description 8
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 8
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 8
• 208000005615 Interstitial Cystitis Diseases 0.000 description 8
• 244000062730 Melissa officinalis Species 0.000 description 8
• 235000010654 Melissa officinalis Nutrition 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 206010042276 Subacute endocarditis Diseases 0.000 description 8
• 210000000845 cartilage Anatomy 0.000 description 8
• 238000004132 cross linking Methods 0.000 description 8
• 230000034994 death Effects 0.000 description 8
• 201000002491 encephalomyelitis Diseases 0.000 description 8
• 210000003743 erythrocyte Anatomy 0.000 description 8
• 230000002519 immonomodulatory effect Effects 0.000 description 8
• 238000011534 incubation Methods 0.000 description 8
• 238000003780 insertion Methods 0.000 description 8
• 230000037431 insertion Effects 0.000 description 8
• 239000000865 liniment Substances 0.000 description 8
• 239000006210 lotion Substances 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 239000003921 oil Substances 0.000 description 8
• 230000008506 pathogenesis Effects 0.000 description 8
• 239000013612 plasmid Substances 0.000 description 8
• 201000000306 sarcoidosis Diseases 0.000 description 8
• 239000002453 shampoo Substances 0.000 description 8
• 210000002784 stomach Anatomy 0.000 description 8
• 208000008467 subacute bacterial endocarditis Diseases 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• 206010009900 Colitis ulcerative Diseases 0.000 description 7
• 102000008186 Collagen Human genes 0.000 description 7
• 108010035532 Collagen Proteins 0.000 description 7
• 108020004414 DNA Proteins 0.000 description 7
• 201000004624 Dermatitis Diseases 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 108010074328 Interferon-gamma Proteins 0.000 description 7
• 206010030113 Oedema Diseases 0.000 description 7
• 101150026634 SAA3 gene Proteins 0.000 description 7
• 201000006704 Ulcerative Colitis Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000003110 anti-inflammatory effect Effects 0.000 description 7
• 238000000576 coating method Methods 0.000 description 7
• 229920001436 collagen Polymers 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 239000006260 foam Substances 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 230000006698 induction Effects 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 230000000670 limiting effect Effects 0.000 description 7
• 230000000926 neurological effect Effects 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 238000005406 washing Methods 0.000 description 7
• 108010078791 Carrier Proteins Proteins 0.000 description 6
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 6
• 208000009386 Experimental Arthritis Diseases 0.000 description 6
• 208000007882 Gastritis Diseases 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• 208000002193 Pain Diseases 0.000 description 6
• 201000004681 Psoriasis Diseases 0.000 description 6
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
• 206010037549 Purpura Diseases 0.000 description 6
• 241001672981 Purpura Species 0.000 description 6
• 206010046851 Uveitis Diseases 0.000 description 6
• 150000001408 amides Chemical class 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000007853 buffer solution Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 6
• 230000009615 deamination Effects 0.000 description 6
• 238000006481 deamination reaction Methods 0.000 description 6
• 230000007812 deficiency Effects 0.000 description 6
• 239000000833 heterodimer Substances 0.000 description 6
• 201000006362 hypersensitivity vasculitis Diseases 0.000 description 6
• 210000000987 immune system Anatomy 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• 210000000936 intestine Anatomy 0.000 description 6
• 238000002156 mixing Methods 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 230000001575 pathological effect Effects 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 201000003068 rheumatic fever Diseases 0.000 description 6
• 210000002966 serum Anatomy 0.000 description 6
• 230000008771 sex reversal Effects 0.000 description 6
• 206010043778 thyroiditis Diseases 0.000 description 6
• 210000001519 tissue Anatomy 0.000 description 6
• 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 5
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 5
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 5
• 206010001935 American trypanosomiasis Diseases 0.000 description 5
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
• 206010003645 Atopy Diseases 0.000 description 5
• 206010069002 Autoimmune pancreatitis Diseases 0.000 description 5
• 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 5
• 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 description 5
• 208000009137 Behcet syndrome Diseases 0.000 description 5
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 5
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 5
• 208000009766 Blau syndrome Diseases 0.000 description 5
• 208000014644 Brain disease Diseases 0.000 description 5
• 102000014914 Carrier Proteins Human genes 0.000 description 5
• 208000005024 Castleman disease Diseases 0.000 description 5
• 208000024699 Chagas disease Diseases 0.000 description 5
• 206010008748 Chorea Diseases 0.000 description 5
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 5
• 208000010007 Cogan syndrome Diseases 0.000 description 5
• 208000027205 Congenital disease Diseases 0.000 description 5
• 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 5
• 208000016192 Demyelinating disease Diseases 0.000 description 5
• 206010012438 Dermatitis atopic Diseases 0.000 description 5
• 208000032274 Encephalopathy Diseases 0.000 description 5
• 201000009273 Endometriosis Diseases 0.000 description 5
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 5
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 5
• 208000029470 Hughes-Stovin syndrome Diseases 0.000 description 5
• 208000010159 IgA glomerulonephritis Diseases 0.000 description 5
• 206010021263 IgA nephropathy Diseases 0.000 description 5
• 102100037850 Interferon gamma Human genes 0.000 description 5
• 208000003456 Juvenile Arthritis Diseases 0.000 description 5
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 5
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 5
• 206010024434 Lichen sclerosus Diseases 0.000 description 5
• 208000009777 Majeed syndrome Diseases 0.000 description 5
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 5
• 206010027982 Morphoea Diseases 0.000 description 5
• 206010028424 Myasthenic syndrome Diseases 0.000 description 5
• 201000002481 Myositis Diseases 0.000 description 5
• 108700026244 Open Reading Frames Proteins 0.000 description 5
• 208000025174 PANDAS Diseases 0.000 description 5
• 206010053869 POEMS syndrome Diseases 0.000 description 5
• 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 5
• 208000004788 Pars Planitis Diseases 0.000 description 5
• 201000011152 Pemphigus Diseases 0.000 description 5
• 208000031845 Pernicious anaemia Diseases 0.000 description 5
• 206010065159 Polychondritis Diseases 0.000 description 5
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 5
• 208000005793 Restless legs syndrome Diseases 0.000 description 5
• 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 5
• 241000194017 Streptococcus Species 0.000 description 5
• 208000010265 Sweet syndrome Diseases 0.000 description 5
• 208000027522 Sydenham chorea Diseases 0.000 description 5
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 5
• 206010051526 Tolosa-Hunt syndrome Diseases 0.000 description 5
• 241000223109 Trypanosoma cruzi Species 0.000 description 5
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
• 230000002776 aggregation Effects 0.000 description 5
• 238000004220 aggregation Methods 0.000 description 5
• 208000004631 alopecia areata Diseases 0.000 description 5
• 125000003275 alpha amino acid group Chemical group 0.000 description 5
• 210000001367 artery Anatomy 0.000 description 5
• 201000008937 atopic dermatitis Diseases 0.000 description 5
• 208000010668 atopic eczema Diseases 0.000 description 5
• 208000001974 autoimmune enteropathy Diseases 0.000 description 5
• 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 description 5
• 206010071572 autoimmune progesterone dermatitis Diseases 0.000 description 5
• 208000000594 bullous pemphigoid Diseases 0.000 description 5
• 238000007385 chemical modification Methods 0.000 description 5
• 208000037976 chronic inflammation Diseases 0.000 description 5
• 230000006020 chronic inflammation Effects 0.000 description 5
• 230000015271 coagulation Effects 0.000 description 5
• 238000005345 coagulation Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 239000000470 constituent Substances 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 201000001981 dermatomyositis Diseases 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 201000004997 drug-induced lupus erythematosus Diseases 0.000 description 5
• 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 description 5
• 201000001505 hemoglobinuria Diseases 0.000 description 5
• 239000000710 homodimer Substances 0.000 description 5
• 230000036039 immunity Effects 0.000 description 5
• 238000009169 immunotherapy Methods 0.000 description 5
• 201000008319 inclusion body myositis Diseases 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 5
• 206010028417 myasthenia gravis Diseases 0.000 description 5
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 5
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 5
• 208000028780 ocular motility disease Diseases 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 201000005580 palindromic rheumatism Diseases 0.000 description 5
• 201000001976 pemphigus vulgaris Diseases 0.000 description 5
• 208000027232 peripheral nervous system disease Diseases 0.000 description 5
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
• 208000005987 polymyositis Diseases 0.000 description 5
• 239000013641 positive control Substances 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000017854 proteolysis Effects 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 201000000980 schizophrenia Diseases 0.000 description 5
• 239000006228 supernatant Substances 0.000 description 5
• 230000008961 swelling Effects 0.000 description 5
• 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 description 5
• 206010043207 temporal arteritis Diseases 0.000 description 5
• 206010043554 thrombocytopenia Diseases 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000002588 toxic effect Effects 0.000 description 5
• 208000009174 transverse myelitis Diseases 0.000 description 5
• 210000000707 wrist Anatomy 0.000 description 5
• 102100036126 60S ribosomal protein L37a Human genes 0.000 description 4
• 208000002874 Acne Vulgaris Diseases 0.000 description 4
• 208000026872 Addison Disease Diseases 0.000 description 4
• 208000002485 Adiposis dolorosa Diseases 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 4
• 201000002829 CREST Syndrome Diseases 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 201000000724 Chronic recurrent multifocal osteomyelitis Diseases 0.000 description 4
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 4
• 208000014311 Cushing syndrome Diseases 0.000 description 4
• 208000027219 Deficiency disease Diseases 0.000 description 4
• 206010012442 Dermatitis contact Diseases 0.000 description 4
• 206010012468 Dermatitis herpetiformis Diseases 0.000 description 4
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 4
• 206010015226 Erythema nodosum Diseases 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 4
• 208000024869 Goodpasture syndrome Diseases 0.000 description 4
• 208000003807 Graves Disease Diseases 0.000 description 4
• 208000015023 Graves' disease Diseases 0.000 description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 4
• 206010019939 Herpes gestationis Diseases 0.000 description 4
• 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 description 4
• 208000000239 Hypertrophic Gastritis Diseases 0.000 description 4
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 4
• 208000000209 Isaacs syndrome Diseases 0.000 description 4
• 208000011200 Kawasaki disease Diseases 0.000 description 4
• 208000021642 Muscular disease Diseases 0.000 description 4
• 201000009623 Myopathy Diseases 0.000 description 4
• 206010029164 Nephrotic syndrome Diseases 0.000 description 4
• 206010029229 Neuralgic amyotrophy Diseases 0.000 description 4
• 206010072359 Neuromyotonia Diseases 0.000 description 4
• 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 description 4
• 208000008223 Pemphigoid Gestationis Diseases 0.000 description 4
• 208000000766 Pityriasis Lichenoides Diseases 0.000 description 4
• 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 description 4
• 208000008601 Polycythemia Diseases 0.000 description 4
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 4
• 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 4
• 208000012322 Raynaud phenomenon Diseases 0.000 description 4
• PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
• 206010039085 Rhinitis allergic Diseases 0.000 description 4
• 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 4
• 201000009594 Systemic Scleroderma Diseases 0.000 description 4
• 206010042953 Systemic sclerosis Diseases 0.000 description 4
• 208000001106 Takayasu Arteritis Diseases 0.000 description 4
• 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 4
• 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 206010000496 acne Diseases 0.000 description 4
• 125000002252 acyl group Chemical group 0.000 description 4
• 239000000443 aerosol Substances 0.000 description 4
• 125000000217 alkyl group Chemical group 0.000 description 4
• 201000010105 allergic rhinitis Diseases 0.000 description 4
• 125000003277 amino group Chemical group 0.000 description 4
• 208000007502 anemia Diseases 0.000 description 4
• 210000003423 ankle Anatomy 0.000 description 4
• 230000002456 anti-arthritic effect Effects 0.000 description 4
• 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 4
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 4
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 4
• 201000004339 autoimmune neuropathy Diseases 0.000 description 4
• 208000029407 autoimmune urticaria Diseases 0.000 description 4
• 201000004982 autoimmune uveitis Diseases 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 235000013339 cereals Nutrition 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 4
• 208000024376 chronic urticaria Diseases 0.000 description 4
• 210000000078 claw Anatomy 0.000 description 4
• 230000000295 complement effect Effects 0.000 description 4
• 208000010247 contact dermatitis Diseases 0.000 description 4
• 201000003278 cryoglobulinemia Diseases 0.000 description 4
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 4
• 238000001212 derivatisation Methods 0.000 description 4
• 230000009266 disease activity Effects 0.000 description 4
• 235000013399 edible fruits Nutrition 0.000 description 4
• 235000013601 eggs Nutrition 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 206010014910 enthesopathy Diseases 0.000 description 4
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 4
• 150000002148 esters Chemical class 0.000 description 4
• 208000002980 facial hemiatrophy Diseases 0.000 description 4
• 230000004761 fibrosis Effects 0.000 description 4
• 230000034659 glycolysis Effects 0.000 description 4
• 230000013595 glycosylation Effects 0.000 description 4
• 238000006206 glycosylation reaction Methods 0.000 description 4
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• 201000011486 lichen planus Diseases 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 4
• 208000009928 nephrosis Diseases 0.000 description 4
• 231100001027 nephrosis Toxicity 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 201000001119 neuropathy Diseases 0.000 description 4
• 230000007823 neuropathy Effects 0.000 description 4
• 230000000422 nocturnal effect Effects 0.000 description 4
• 230000001717 pathogenic effect Effects 0.000 description 4
• 230000010412 perfusion Effects 0.000 description 4
• 230000008823 permeabilization Effects 0.000 description 4
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 4
• 238000011321 prophylaxis Methods 0.000 description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 description 4
• 238000003753 real-time PCR Methods 0.000 description 4
• 208000009169 relapsing polychondritis Diseases 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 238000010839 reverse transcription Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 230000028327 secretion Effects 0.000 description 4
• 206010040400 serum sickness Diseases 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 238000005507 spraying Methods 0.000 description 4
• 230000008685 targeting Effects 0.000 description 4
• TWNIBLMWSKIRAT-RWOPYEJCSA-N (1r,2s,3s,4s,5r)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol Chemical compound O1[C@@]2([H])OC[C@]1([H])[C@@H](O)[C@H](O)[C@@H]2O TWNIBLMWSKIRAT-RWOPYEJCSA-N 0.000 description 3
• XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
• 206010071155 Autoimmune arthritis Diseases 0.000 description 3
• 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 102100035904 Caspase-1 Human genes 0.000 description 3
• 108090000426 Caspase-1 Proteins 0.000 description 3
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 3
• 102000002734 Collagen Type VI Human genes 0.000 description 3
• 108010043741 Collagen Type VI Proteins 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• 108700039887 Essential Genes Proteins 0.000 description 3
• 102000003777 Interleukin-1 beta Human genes 0.000 description 3
• 108090000193 Interleukin-1 beta Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 3
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 108091005804 Peptidases Proteins 0.000 description 3
• 206010037660 Pyrexia Diseases 0.000 description 3
• 208000034189 Sclerosis Diseases 0.000 description 3
• 241000282898 Sus scrofa Species 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000004913 activation Effects 0.000 description 3
• 208000038016 acute inflammation Diseases 0.000 description 3
• 230000006022 acute inflammation Effects 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 229940124599 anti-inflammatory drug Drugs 0.000 description 3
• 238000004820 blood count Methods 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000012267 brine Substances 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 208000013507 chronic prostatitis Diseases 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 208000018631 connective tissue disease Diseases 0.000 description 3
• 230000008878 coupling Effects 0.000 description 3
• 238000010168 coupling process Methods 0.000 description 3
• 238000005859 coupling reaction Methods 0.000 description 3
• 238000005336 cracking Methods 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 230000003210 demyelinating effect Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 229940126534 drug product Drugs 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 230000001605 fetal effect Effects 0.000 description 3
• 239000000835 fiber Substances 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 3
• 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 230000002045 lasting effect Effects 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 206010025482 malaise Diseases 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 244000005700 microbiome Species 0.000 description 3
• 208000008795 neuromyelitis optica Diseases 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 230000003950 pathogenic mechanism Effects 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 201000007094 prostatitis Diseases 0.000 description 3
• 238000011002 quantification Methods 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011069 regeneration method Methods 0.000 description 3
• 230000009711 regulatory function Effects 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• 208000010157 sclerosing cholangitis Diseases 0.000 description 3
• 208000013223 septicemia Diseases 0.000 description 3
• 230000035939 shock Effects 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 201000004595 synovitis Diseases 0.000 description 3
• 238000012795 verification Methods 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
• 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 102400000107 C-terminal peptide Human genes 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 2
• 208000021866 Dressler syndrome Diseases 0.000 description 2
• 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
• 101710121417 Envelope glycoprotein Proteins 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 102000003886 Glycoproteins Human genes 0.000 description 2
• 108090000288 Glycoproteins Proteins 0.000 description 2
• 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020651 Hyperkinesia Diseases 0.000 description 2
• 208000000269 Hyperkinesis Diseases 0.000 description 2
• 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 2
• 102000013462 Interleukin-12 Human genes 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 108010082786 Interleukin-1alpha Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 241000712079 Measles morbillivirus Species 0.000 description 2
• 102000018697 Membrane Proteins Human genes 0.000 description 2
• 108010052285 Membrane Proteins Proteins 0.000 description 2
• 108091092878 Microsatellite Proteins 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
• 208000003926 Myelitis Diseases 0.000 description 2
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
• 206010053159 Organ failure Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241001111421 Pannus Species 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 102000004257 Potassium Channel Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
• 238000001190 Q-PCR Methods 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 201000010848 Schnitzler Syndrome Diseases 0.000 description 2
• 102000054727 Serum Amyloid A Human genes 0.000 description 2
• 101710190759 Serum amyloid A protein Proteins 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 201000001322 T cell deficiency Diseases 0.000 description 2
• 102000002689 Toll-like receptor Human genes 0.000 description 2
• 108020000411 Toll-like receptor Proteins 0.000 description 2
• 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 241000711975 Vesicular stomatitis virus Species 0.000 description 2
• 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 2
• 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 150000001450 anions Chemical class 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 208000002352 blister Diseases 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 230000021523 carboxylation Effects 0.000 description 2
• 238000006473 carboxylation reaction Methods 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000011748 cell maturation Effects 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 239000013626 chemical specie Substances 0.000 description 2
• 208000003167 cholangitis Diseases 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 230000000911 decarboxylating effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000022811 deglycosylation Effects 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 229950006137 dexfosfoserine Drugs 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 206010014665 endocarditis Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 208000037902 enteropathy Diseases 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 210000003754 fetus Anatomy 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 230000001279 glycosylating effect Effects 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 210000002216 heart Anatomy 0.000 description 2
• 210000003709 heart valve Anatomy 0.000 description 2
• 230000000004 hemodynamic effect Effects 0.000 description 2
• 229920002674 hyaluronan Polymers 0.000 description 2
• KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
• 229940099552 hyaluronan Drugs 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000008629 immune suppression Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 208000028774 intestinal disease Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 210000001503 joint Anatomy 0.000 description 2
• 210000000629 knee joint Anatomy 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 210000002429 large intestine Anatomy 0.000 description 2
• 229960004194 lidocaine Drugs 0.000 description 2
• 210000003041 ligament Anatomy 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 230000009871 nonspecific binding Effects 0.000 description 2
• 238000010606 normalization Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 210000001328 optic nerve Anatomy 0.000 description 2
• 230000004768 organ dysfunction Effects 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
• USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 210000002381 plasma Anatomy 0.000 description 2
• 108020001213 potassium channel Proteins 0.000 description 2
• 150000003141 primary amines Chemical class 0.000 description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
• 230000002784 sclerotic effect Effects 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 210000001258 synovial membrane Anatomy 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 210000004885 white matter Anatomy 0.000 description 2
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• 108020004463 18S ribosomal RNA Proteins 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
• 101150037123 APOE gene Proteins 0.000 description 1
• 206010048998 Acute phase reaction Diseases 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 239000012099 Alexa Fluor family Substances 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 241001614291 Anoplistes Species 0.000 description 1
• 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 102100029470 Apolipoprotein E Human genes 0.000 description 1
• 102000013918 Apolipoproteins E Human genes 0.000 description 1
• 108010025628 Apolipoproteins E Proteins 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• 206010071576 Autoimmune aplastic anaemia Diseases 0.000 description 1
• 201000008162 B cell deficiency Diseases 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 238000011729 BALB/c nude mouse Methods 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 102000003846 Carbonic anhydrases Human genes 0.000 description 1
• 108090000209 Carbonic anhydrases Proteins 0.000 description 1
• 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
• 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
• 241000282994 Cervidae Species 0.000 description 1
• 241000283153 Cetacea Species 0.000 description 1
• 241000905957 Channa melasoma Species 0.000 description 1
• 108091006146 Channels Proteins 0.000 description 1
• 102000034573 Channels Human genes 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 241000219104 Cucurbitaceae Species 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 241001115402 Ebolavirus Species 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 206010058838 Enterocolitis infectious Diseases 0.000 description 1
• 206010049466 Erythroblastosis Diseases 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 206010061958 Food Intolerance Diseases 0.000 description 1
• 206010016946 Food allergy Diseases 0.000 description 1
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
• 102100035233 Furin Human genes 0.000 description 1
• 108090001126 Furin Proteins 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 241000235503 Glomus Species 0.000 description 1
• 229920001503 Glucan Polymers 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010093013 HLA-DR1 Antigen Proteins 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000192019 Human endogenous retrovirus K Species 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000027601 Inner ear disease Diseases 0.000 description 1
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000013691 Interleukin-17 Human genes 0.000 description 1
• 108050003558 Interleukin-17 Proteins 0.000 description 1
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 102000037862 Ion Transporter Human genes 0.000 description 1
• 108091006671 Ion Transporter Proteins 0.000 description 1
• 206010060820 Joint injury Diseases 0.000 description 1
• 206010023232 Joint swelling Diseases 0.000 description 1
• 150000008540 L-glutamines Chemical class 0.000 description 1
• 208000017119 Labyrinth disease Diseases 0.000 description 1
• 208000008771 Lymphadenopathy Diseases 0.000 description 1
• 206010027336 Menstruation delayed Diseases 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
• 101150076359 Mhc gene Proteins 0.000 description 1
• 208000010718 Multiple Organ Failure Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 241000699729 Muridae Species 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• 206010050031 Muscle strain Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 241001597008 Nomeidae Species 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 108010058846 Ovalbumin Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 208000004210 Pressure Ulcer Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
• 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 206010061926 Purulence Diseases 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 206010038743 Restlessness Diseases 0.000 description 1
• 206010038997 Retroviral infections Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 108700028909 Serum Amyloid A Proteins 0.000 description 1
• 238000003457 Shi epoxidation reaction Methods 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 102000018674 Sodium Channels Human genes 0.000 description 1
• 108010052164 Sodium Channels Proteins 0.000 description 1
• 206010042220 Stress ulcer Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 210000004241 Th2 cell Anatomy 0.000 description 1
• 208000002474 Tinea Diseases 0.000 description 1
• 241000130764 Tinea Species 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 108700019146 Transgenes Proteins 0.000 description 1
• 241000819233 Tribulus <sea snail> Species 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004658 acute-phase response Effects 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 210000005006 adaptive immune system Anatomy 0.000 description 1
• 208000013228 adenopathy Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003172 anti-dna Effects 0.000 description 1
• 239000003435 antirheumatic agent Substances 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000025255 bacterial arthritis Diseases 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000037058 blood plasma level Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 239000001045 blue dye Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 239000002639 bone cement Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 208000030270 breast disease Diseases 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000034303 cell budding Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 210000003477 cochlea Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 201000003056 complement component 2 deficiency Diseases 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 239000000306 component Substances 0.000 description 1
• 239000002131 composite material Substances 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 238000010219 correlation analysis Methods 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000006114 decarboxylation reaction Methods 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 239000004053 dental implant Substances 0.000 description 1
• 108010016290 deoxyribonucleoprotamine Proteins 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000002542 deteriorative effect Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 208000007784 diverticulitis Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 238000004043 dyeing Methods 0.000 description 1
• 235000014103 egg white Nutrition 0.000 description 1
• 210000000969 egg white Anatomy 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
• 101150030339 env gene Proteins 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 210000003617 erythrocyte membrane Anatomy 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• WVRIJHGUJNXDRZ-UHFFFAOYSA-N ethane-1,1-diamine Chemical class CC(N)N WVRIJHGUJNXDRZ-UHFFFAOYSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 210000003811 finger Anatomy 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000012921 fluorescence analysis Methods 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 230000000799 fusogenic effect Effects 0.000 description 1
• 108010074605 gamma-Globulins Proteins 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000002641 glycemic effect Effects 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• 230000002962 histologic effect Effects 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 208000036260 idiopathic disease Diseases 0.000 description 1
• 230000008102 immune modulation Effects 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000010185 immunofluorescence analysis Methods 0.000 description 1
• 238000010820 immunofluorescence microscopy Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000007365 immunoregulation Effects 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 208000027139 infectious colitis Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 230000003960 inflammatory cascade Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000008946 inflammatory intestinal reaction Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003978 infusion fluid Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 229910001410 inorganic ion Inorganic materials 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 210000001613 integumentary system Anatomy 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
• 230000010189 intracellular transport Effects 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 208000001875 irritant dermatitis Diseases 0.000 description 1
• 208000018937 joint inflammation Diseases 0.000 description 1
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 208000018191 liver inflammation Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 230000004199 lung function Effects 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 238000005399 mechanical ventilation Methods 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000029052 metamorphosis Effects 0.000 description 1
• 235000006109 methionine Nutrition 0.000 description 1
• 125000001360 methionine group Chemical class N[C@@H](CCSC)C(=O)* 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000272 myelencephalon Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 230000002151 myoclonic effect Effects 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• 229940092253 ovalbumin Drugs 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 210000003899 penis Anatomy 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 230000007096 poisonous effect Effects 0.000 description 1
• 239000002861 polymer material Substances 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000002601 radiography Methods 0.000 description 1
• 238000012755 real-time RT-PCR analysis Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 238000007670 refining Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000036387 respiratory rate Effects 0.000 description 1
• 108700004030 rev Genes Proteins 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 208000007442 rickets Diseases 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 210000004406 stave cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000005065 subchondral bone plate Anatomy 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000002344 surface layer Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 210000002437 synoviocyte Anatomy 0.000 description 1
• 230000008718 systemic inflammatory response Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• 210000003684 theca cell Anatomy 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 229940047183 tribulus Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 210000000251 trophoblastic cell Anatomy 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000012646 vaccine adjuvant Substances 0.000 description 1
• 229940124931 vaccine adjuvant Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 210000000605 viral structure Anatomy 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1